Boston Scientific Corporation
$50.37
The Read: Boston Scientific's stock has historically plunged over 18% on cautious or disappointing FY guidance despite earnings beats, declined about 11% amid regulatory scrutiny on M&A, and rallied roughly 13% when strong quarterly results and cost-saving plans outweighed lowered full-year outlooks.
BSX
Hover to view data
No Data